Evidence map›Paper›PMID 36104608›Full record

ReviewCellular and molecular neurobiology2023

The Critical Role of RNA m

Zhouhan Xu, Jun Jiang, Shun Wang

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cellular and molecular neurobiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. The therapeutic potential of RNA m(6)A in lung cancer.Cell communication and signaling : CCS · 2024
    Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Zhouhan XuThe Second Hospital of Shandong University, Jinan, 250012, Shandong, People's Republic of China.ORCID http://orcid.org/0000-0003-4074-2853
Jun JiangDepartment of Neurosurgery, The Second Hospital of Shandong University, 247 Beiyuan Road, Jinan, 250012, Shandong, People's Republic of China. jiangjun@sdu.edu.cn.ORCID http://orcid.org/0000-0002-0560-8889
Shun WangDepartment of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, 250012, Shandong, People's Republic of China.ORCID http://orcid.org/0000-0001-7907-7112
Second Hospital of Shandong University · CN

Funding

Young Scientists Fund 82000559
6 · The paper itself

Abstract

Gliomas are the most common central cancer with high aggressive-capacity and poor prognosis, remaining to be the threat of most patients. With the blood-brain barrier and highly malignant progression, the efficacy of high-intensity treatment is limited. The N6-methyladenine (m

Indexed as

GliomaMicroRNAsApoptosisHumansMethylationRNA, MessengerTumor MicroenvironmentMicroRNAsRNA, MessengerGliomam6A modificationMalignant progressionMetabolism reprogrammingPhenotypic plasticityTumor microenvironment

Identifiers

PMID36104608
PMCPMC11412196
OpenAlexW4295779302

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.